Clinical Trials
9 results for Kidney/Renal Cancer
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- Condition: Renal Cell Carcinoma
- Intervention: Device: CyberKnife
- Study ID: NCT01890590
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.
- Condition: Thyroid Cancer, Medullary
- Intervention: Drug: 177Lu-PP-F11N
- Study ID: NCT02088645
Kidney Cancer DNA Registry
- Condition: Renal Cancer
- Intervention: Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable)
- Study ID: NCT02087852
Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers
- Condition: Clear Renal Cell Cancer (< 7cm Size)
- Intervention: Procedure: Partial or radical nephrectomy
- Study ID: NCT03694912
Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors
- Condition: Renal Tumor
- Intervention: Radiation: Stereotactic Ablative Radiotherapy
- Study ID: NCT03747133
Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies
- Condition: Clear Cell Renal Cell Carcinoma, Locally Advance Pancreatic Ductal Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Pancreatic Ductal Ad
- Intervention: Drug: ATR Kinase Inhibitor AZD6738, Drug: Olaparib
- Study ID: NCT03682289
An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse
- Condition: Renal Cell Carcinoma
- Intervention: Drug: Durvalumab, Drug: Tremelimumab
- Study ID: NCT03288532
Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study
- Condition: Advanced Renal Cell Carcinoma
- Intervention: Other: Carevive software
- Study ID: NCT03229083
Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
- Condition: Renal Cell Carcinoma
- Intervention: Drug: Nivolumab, Drug: Axitinib
- Study ID: NCT03172754